 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Topical, rectal |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.017.683 |
| Chemical and physical data | |
| Formula | C12H17NO3 |
| Molar mass | 223.272 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bufexamac is a drug used as ananti-inflammatory agent on the skin, as well asrectally. Common brand names includeParaderm andParfenac. It was withdrawn in Europe and Australia[1] because of allergic reactions.
Ointments and lotions containing bufexamac are used for the treatment of subacute and chroniceczema of the skin, includingatopic eczema, as well assunburn and other minor burns,[citation needed] anditching.Suppositories containing bufexamac in combination withlocal anaesthetics are used againsthaemorrhoids.[2]
Bufexamac is thought to act by inhibiting the enzymecyclooxygenase, which would make it anon-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce.[3]Furthermore, bufexamac was identified as a specific inhibitor of class IIBhistone deacetylases (HDAC6 andHDAC10).[4]
Bufexamac can cause severecontact dermatitis which is often hard to distinguish from the initial condition.[5] As a consequence, theEuropean Medicines Agency recommended to withdraw the marketing approval in April 2010.[6]
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key:underline indicates initially developed first-in-class compound of specific group;#WHO-Essential Medicines;†withdrawn drugs;‡veterinary use. | |
